SCHEMBL5024067

SCHEMBL5024067

c1ccc(CSc2nnc(-c3ccncc3)o2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 13/20 1.00
GSK3A P49840 8/20 1.00
HTT P42858 5/20 1.00
NPC1 O15118 3/20 1.00
ALDH1A1 P00352 2/20 1.00
MAPK1 P28482 2/20 1.00
RAB9A P51151 2/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
EGFR P00533 1/20 0.82
SMN1; SMN2 Q16637 2/20 0.74
NCOA1 Q15788 1/20 0.74
NCOA3 Q9Y6Q9 1/20 0.74
POLB P06746 1/20 0.72
CCNB2 O95067 1/20 0.71
CDK1 P06493 1/20 0.71
CCNB1 P14635 1/20 0.71
CCNB3 Q8WWL7 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16157157 0.94 GSK3B (0.89) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL14604409 0.93 GSK3B (1.00) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL16944477 0.92 GSK3B (0.85) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL928258 0.91 EGFR (1.00) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL14603763 0.89 GSK3B (0.80) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL16944450 0.88 GSK3B (0.78) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL16157074 0.88 EGFR (0.94) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL16944463 0.87 RAB9A (0.79) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL5024100 0.87 GSK3B (1.00) GSK3BGSK3AHTTNPC1ALDH1A1
SCHEMBL16157177 0.85 GSK3B (1.00) GSK3BGSK3AHTTNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111568903-A Application of bioactive molecule and derivative thereof in preparation of HIV-1 expression inhibitor 中山大学 2020-08-25 CN claimed
CN-111568903-A Application of bioactive molecule and derivative thereof in preparation of HIV-1 expression inhibitor 中山大学 2020-08-25 CN disclosed
CN-111568903-A Application of bioactive molecule and derivative thereof in preparation of HIV-1 expression inhibitor 中山大学 2020-08-25 CN disclosed
US-20200140425-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS MASSACHUSETTS GENERAL HOSPITAL 2020-05-07 US disclosed
US-10301294-B2 Compounds for the treatment of tuberculosis The Broad Institute Inc. (US) 2019-05-28 US disclosed
US-9669014-B2 Small molecule inhibitors of superoxide dismutase expression NORTHWESTERN UNIVERSITY (US) 2017-06-06 US disclosed
US-9669014-B2 Small molecule inhibitors of superoxide dismutase expression NORTHWESTERN UNIVERSITY (US) 2017-06-06 US disclosed
US-20160214969-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION NORTHWESTERN UNIVERSITY (US) 2016-07-28 US disclosed
US-20160214969-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION NORTHWESTERN UNIVERSITY (US) 2016-07-28 US disclosed
US-20160031870-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS NIH - DEITR 2016-02-04 US disclosed
US-20160031870-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS NIH - DEITR 2016-02-04 US disclosed
US-20150210679-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION NORTHWESTERN UNIVERSITY (US) 2015-07-30 US disclosed
US-20150210679-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION NORTHWESTERN UNIVERSITY (US) 2015-07-30 US disclosed
WO-2014165090-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS THE BROAD INSTITUTE, INC. (US) 2014-10-09 WO disclosed
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
WO-2013007663-A1 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF Technische Universität Darmstadt (DE) 2013-01-17 WO disclosed
WO-2012065065-A9 METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION FOLLICA, INC. (US) 2012-10-11 WO disclosed
WO-2012065065-A1 METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION FOLLICA, INC. (US) 2012-05-18 WO disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214969-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION SOD1, SOD3, CAT GSK3B 2605/4885GSK3A 2565/4885HTT 723/4885
US-10301294-B2 Compounds for the treatment of tuberculosis GOT2, G6PD, FNTB GSK3B 2519/4885GSK3A 2959/4885HTT 4103/4885
US-20200140425-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS GOT2, G6PD, FNTB GSK3B 2519/4885GSK3A 2959/4885HTT 4103/4885
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP GSK3B 1/4885GSK3A 2/4885HTT 3480/4885
US-20150210679-A1 SMALL MOLECULE INHIBITORS OF SUPEROXIDE DISMUTASE EXPRESSION SOD1, SOD3, CAT GSK3B 2605/4885GSK3A 2565/4885HTT 723/4885
US-20160031870-A1 COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS GOT2, G6PD, FNTB GSK3B 2519/4885GSK3A 2959/4885HTT 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.